🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

Related News

Genexis Biotech raises Rs 4 Cr in seed round led by GVFL

EntrackrEntrackr · 7m ago
Genexis Biotech raises Rs 4 Cr in seed round led by GVFL
Medial

Genexis Biotech raises Rs 4 Cr in seed round led by GVFL Vadodara-based bio-manufacturing startup Genexis Biotech has raised Rs 4 crore in a seed funding round led by GVFL, with participation from Benzai10. The proceeds will be used to scale bioreactor capacity, build downstream processing infrastructure, launch new recombinant proteins and enzymes, and strengthen compliance, sales, and distribution functions. Genexis Biotech develops animal-origin-free recombinant proteins using precision fermentation, catering to sectors like biopharma, food-tech, and cell culture. The startup operates a certified Class 10,000 facility and is setting up a GMP-compliant unit. It has introduced recombinant peptidases such as amino peptidase and enterokinase, and plans to launch recombinant transferrin and albumin. In the past year, Genexis established partnerships with pharmaceutical companies and biotech firms, signed an MoU with the Gujarat government, and received client orders for alternative protein formulations. It showcased its portfolio at Global Bio-India 2024 and aims to enter the regulated biotech export market, develop encapsulated formulations for the cosmetics industry, and collaborate with CDMOs, academic labs, and biopharma firms. Genexis Biotech focuses on scalable, ethical biomolecule production. GVFL has backed the company as part of its investment thesis across deeptech and biotech innovation.

Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group

EntrackrEntrackr · 8m ago
Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group
Medial

Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group Lamark's proprietary ProteoStrong platform enables the stabilization of fragile protein-based drugs, such as insulin, monoclonal antibodies, and enzymes, without altering their molecular structure. Biopharma startup Lamark Biotech has raised Rs 6.5 crore in a pre-Series A round led by IAN Group, including IAN Alpha Fund, powered by BioAngels, Vinayender Tulla, Nita Roy, and Venkataraman KNK. Domain experts from IAN’s angel investors led the round. The Ahmedabad-based company had previously raised $41.3K in a seed funding round led by VIT-TBI and others. The fresh funds will be utilized to accelerate the development of thermostable insulin and expand the biologics platform for global access, Lamark said in a press release. Founded in 2018 by Vaibhav Bhatia, Lamark Biotech aims to reimagine drug delivery for chronic and life-altering diseases. Its proprietary ProteoStrong platform enables the stabilization of fragile protein-based drugs, such as insulin, monoclonal antibodies, and enzymes, without altering their molecular structure. According to Lamark Biotech, it leverages the R&D base of Venture Center, NCL Innovation, and it is advancing a new class of temperature-resilient biologics that retain potency across extreme conditions—ideal for underserved regions where cold storage infrastructure is limited. With its lead program, InsulinStrong, Lamark is targeting the Rs 4,000 crore Indian insulin market and intends to expand across Southeast Asia and the UAE. In the next 24 months, it plans to file new international patents, begin early clinical trials, and build partnerships with pharma companies, CDMOs, and global health agencies.

Biotech startup Pandorum Technologies raises $18 Mn in Series B round

EntrackrEntrackr · 18d ago
Biotech startup Pandorum Technologies raises $18 Mn in Series B round
Medial

Biotech startup Pandorum Technologies raises $18 Mn in Series B round Biotech startup Pandorum Technologies has raised $18 million in a Series B funding round led by Protons Corporate, with participation from Galentic Pharma, Ashish Kacholia, Noblevast Advisory, Avinya Fund, and the Burman Family, among others. Entrackr had exclusively reported the current development in November last year. The funding round was completed in two tranches, with the first tranche in November and the second in December. According to Entrackr’s analysis, the company will be valued at around Rs 822 crore (around $91 million) post money. The proceeds will be used to advance clinical programs, scale manufacturing, and expand market access across the U.S., Japan, and the Middle East. A portion of the funds will also be deployed towards strengthening regulatory and clinical capabilities. Founded by Tuhin Bhowmick and Arun Chandru, Pandorum operates in the regenerative medicine and biotechnology space, focusing on programmable, exosome-based tissue regenerative therapies. The company has operations in India and the United States. The brand follows a globally distributed manufacturing strategy. It has partnered with AGC Biologics for manufacturing support in the U.S. and Europe, and Nucelion Therapeutics, a subsidiary of Bharat Biotech, for supply across the Asia-Pacific region. The company is also exploring partnerships in the Middle East. According to TheKredible, the company has raised around $43 million to date, including the $11 million secured last year as an extension of its Series A. Pandorum has yet to file its FY25 financials. In FY24, the company was in a pre-revenue stage and reported losses of Rs 28.2 crore. Disclaimer: Bareback Media has recently raised funding from a group of investors. Some of the investors may directly or indirectly be involved in a competing business or might be associated with other companies we might write about. This shall, however, not influence our reporting or coverage in any manner whatsoever.

Download the medial app to read full posts, comements and news.